Cooper Co (COO) Price & Analysis
COO Stock Chart & Stats
- Day’s Range
- MXN 985.00 - MXN 1,122.24
- 52-Week Range
- MXN 880.00 - MXN 6,046.90
- Previous Close
- MXN 985.00
- Volume
- 0
- Average Volume (3M)
- 1
- Market Cap
- MXN 212.73B
- Enterprise Value
- MXN 16.38B
- Total Cash (Recent Filing)
- MXN 154.70M
- Total Debt (Recent Filing)
- MXN 2.54B
- Price to Earnings (P/E)
- 20.3
- Beta
- 0.22
- Next Earnings
- Dec 03, 2026
- EPS Estimate
- 20.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Balance Sheet
Solid revenue expansion combined with conservative leverage gives Cooper financial capacity to invest in product development, commercial execution and market expansion. This foundation can support resilience through operating volatility and preserve flexibility for disciplined capital allocation over the next several quarters.
Fertility Market Position
Broad portfolio strength and reported global fertility market-share gains indicate that CooperSurgical is building position in a structurally supported market. Continued clinic wins, genomics demand and product adoption can provide durable growth beyond quarterly fluctuations in capital equipment sales.
Vision Innovation Pipeline
MiSight growth, geographic expansion and additional product launches strengthen CooperVision's myopia-management platform. Continued adoption across regions can diversify the vision portfolio, deepen customer relationships and provide a recurring growth avenue supported by ongoing product innovation.
Bears Say
Weak Cash Conversion
The sharp TTM decline in operating and free cash flow weakens earnings quality and reduces internally generated funding for investment, acquisitions or shareholder returns. Even if some pressure proves temporary, sustained cash conversion weakness would constrain financial flexibility and execution.
Operating Margin Pressure
The substantial operating-margin compression shows that revenue growth is not currently translating efficiently into operating profit. Further Q4 pressure from commercial spending, foreign exchange and lower tariff refunds could prolong earnings volatility while investments are absorbed.
CEO Transition And Governance Change
An abrupt CEO departure and interim operating arrangement introduce leadership uncertainty during a period requiring stronger commercial execution and margin recovery. The board refresh may improve governance, but the transition could temporarily complicate strategic continuity and accountability.
Cooper Co News
COO FAQ
What was Cooper Co’s price range in the past 12 months?
What is Cooper Co’s market cap?
When is Cooper Co’s upcoming earnings report date?
How were Cooper Co’s earnings last quarter?
Is Cooper Co overvalued?
Does Cooper Co pay dividends?
What is Cooper Co’s EPS estimate?
How many shares outstanding does Cooper Co have?
What happened to Cooper Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cooper Co?
What is the TipRanks Smart Score and how is it calculated?
Cooper Co Stock Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White
- Employees
- 15,000
- Website
- www.coopercos.com
- Address
- 6101 Bollinger Canyon Road, San Ramon, CA, 94583, US
Cooper Co (COO) Earnings & Revenues
COO Company Deck
COO Earnings Call
Earnings Call SentimentPositive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.
View all MX:COO earnings summariesCOO Net sales Breakdown
- 67.05% CooperVision
- 32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 2 | 11 |
| Technical Analysis | 4 | 2 | 3 |
| Moving Averages | 4 | 0 | 8 |













